UroGen Pharma Ltd. (URGN)

Market Cap	480.17M
Revenue (ttm)	82.71M
Net Income (ttm)	-102.24M
Shares Out	36.13M
EPS (ttm)	-3.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,160
Open	13.31
Previous Close	13.45
Day's Range	13.05 - 13.50
52-Week Range	8.69 - 24.13
Beta	1.08
Analysts	Buy
Price Target	35.33 (+165.54%)
Earnings Date	May 13, 2024

About URGN

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate ris...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 4, 2017
• Employees: 198
• Stock Exchange: NASDAQ
• Ticker Symbol: URGN

Financial Performance

In 2023, UroGen Pharma's revenue was $82.71 million, an increase of 28.52% compared to the previous year's $64.36 million. Losses were -$102.24 million, -6.87% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for URGN stock is "Buy." The 12-month stock price forecast is $35.33, which is an increase of 165.54% from the latest price.

Price Target

$35.33

(165.54% upside)

Analyst Consensus: Buy